Milestone Pharmaceuticals (MIST) Amortization of Deferred Charges (2023 - 2026)

Milestone Pharmaceuticals (MIST) has 4 years of Amortization of Deferred Charges data on file, last reported at $117000.0 in Q1 2026.

• Quarterly Amortization of Deferred Charges rose 14.71% year-over-year to $117000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $447000.0 (up 16.1% YoY) and the FY2025 annual result came in at $432000.0, up 16.76% from the prior year.
• Amortization of Deferred Charges improved to $117000.0 in Q1 2026, from $115000.0 in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $117000.0 in Q1 2026 to a low of $61000.0 in Q2 2023.
• A 4-year average of $93916.7 and a median of $96000.0 in 2024 frame the typical range for Amortization of Deferred Charges.
• Annual changes were most pronounced in 2024 — Amortization of Deferred Charges soared 50.79% — and 2026, when it advanced 14.71%.
• Tracing MIST's Amortization of Deferred Charges over 4 years: stood at $84000.0 in 2023, then rose by 15.48% to $97000.0 in 2024, then gained by 18.56% to $115000.0 in 2025, then rose by 1.74% to $117000.0 in 2026.
• The last three Amortization of Deferred Charges figures came in at $117000.0 (Q1 2026), $115000.0 (Q4 2025), and $109000.0 (Q3 2025), per Business Quant data.